Clinical trial NCT00790218: A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma
Official title: A Phase 1-2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered CF102 in Patients With Advanced Hepatocellular Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Hepatocellular Carcinoma
Keywords: Hepatocellular carcinoma
Hepatoma
HCC
Lead sponsor: Can-Fite BioPharma
Sponsor class: INDUSTRY
First posted: 2008-11-13
Enrollment: 19
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: Study Arms: CF102 (1, 5, and 25 mg BID) in 28-day cycles.
Primary purpose: TREATMENT

Brief summary: This trial will test the safety and efficacy of CF102 in patients with advanced liver cancer. Successive groups of patients will be given higher doses of CF102 by mouth on a twice-daily basis. Treatment will be assessed for adverse effects and for effects on the tumor.

Detailed description: This is a multicenter, open-label, non-randomized, dose-escalation study, to be conducted in 2 phases: a dose-escalation phase, to determine the MTD of CF102 and to evaluate its safety/tolerability, PK, pharmacodynamic, and preliminary clinical activity; and a dose-confirmation phase, which will be a cohort expansion at or below the MTD (ie, the RP2D) of CF102. Subjects will be treated with oral doses of CF102 in consecutive, 28-day cycles. The initial dose of CF102 will be 1 mg twice daily (BID), with subsequent escalations to 5 and 25 mg BID, unless limited by toxicity. Subjects will be evaluated weekly for the first cycle, every 2 weeks for Cycles 2 and 3, and at the end of each subsequent cycle, up to 6 cycles of CF102 treatment. Subjects will return for a follow-up visit 28 days after completion of the last dose of study drug.

Eligibility criteria: Inclusion Criteria:

1. Diagnosis of HCC:

   * For patients without underlying cirrhosis, diagnosis of HCC documented by cytology and/or histology
   * For patients with underlying cirrhosis, diagnosis of HCC established according to the American Association for the Study of Liver Diseases Practice Guideline algorithm (Appendix V).
2. HCC is advanced, refractory, or metastatic, and no standard therapies are expected to be curative.
3. At least 18 years of age.
4. For subjects in the dose-confirmation (RP2D) phase only: Measurable disease, using Response Evaluation Criteria in Solid Tumors (RECIST, Appendix IV). (Note that a lesion that has been subjected to radiotherapy or chemoembolization cannot be used as a target lesion.)
5. Eastern Collaborative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2 at baseline.
6. The following laboratory values must be documented within 3 days prior to initiation of study drug:

   * Absolute neutrophil count (ANC) greater than or equal to 1 x 109/L
   * Platelet count greater than or equal to 50 x 109/L
   * Serum creatinine less than or equal to 2.0 mg/dL
   * Aspartic aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × upper limit of normal.
   * Total bilirubin ≤ 3.0 mg/dL.
   * Serum albumin ≥ 3.0 g/dL.
   * International normalized ratio (INR) ≤ 2.3.
7. Esophageal bleeding and varices, if present, have been sclerosed or banded, and no bleeding episodes have occurred during the prior 6 months.
8. Life expectancy of ≥ 12 weeks.
9. For women of childbearing potential, negative serum pregnancy test result.
10. Absence of active malignancy other than HCC within 2 years of entry, with the exception of basal cell carcinoma and squamous cell carcinoma of the skin.
11. Provide written informed consent to participate.
12. Willing to comply with scheduled visits, treatment plans, laboratory assessments, and other study related procedures.

    -

Exclusion Criteria:

1. Any chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy, corticosteroids \> 20 mg/day prednisone or equivalent, or growth factor treatment (e.g., erythropoietin) within 14 days prior to initiation of study drug.
2. Major surgery or radiation therapy within 28 days prior to initiation of study drug.
3. Severe liver dysfunction (Child-Pugh Class C or hepatic encephalopathy).
4. Active infection requiring systemic therapy.
5. Uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within 3 months prior to initiation of study drug.
6. History of or ongoing cardiac dysrhythmias requiring treatment, atrial fibrillation of any grade, or persistent prolongation of the QTc (Fridericia) interval to \> 450 msec for males or \> 470 msec for females.
7. Pregnant or lactating female.
8. Women of childbearing potential, unless they agree to use dual contraceptive methods which, in the opinion of the Principal Investigator (PI), are effective and adequate for that patient's circumstances while on study drug.
9. Men who partner with a woman of childbearing potential, unless they agree to use effective, dual contraceptive methods (i.e., a condom, with female partner using oral, injectable, or barrier method) while on study drug.
10. Known human immunodeficiency virus- or acquired immunodeficiency syndrome-related illness.
11. Any severe, acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, may interfere with the informed consent process and/or with compliance with the requirements of the study, or may interfere with the interpretation of study results and, in the investigator's opinion, would make the patient inappropriate for entry into this study.

    -

Primary outcomes:
measure: Dose Limiting Toxicity
timeFrame: From start of treatment until Day 28 of Cycle 1
measure: Maximum Tolerated Dose
timeFrame: first 28 days (Cycle 1)
measure: Maximum Plasma Concentration of CF102 (Cmax)
timeFrame: Dose Escalation Phase on Day 1 and Day 29 pre-dose and at 1, 2, 3, 4, 6, 8 hours post-dose
Secondary outcomes:
measure: Number of Subjects With Objective Tumor Response
timeFrame: 6 months
measure: Relationship Between Biomarkers of Peripheral Blood Mononuclear Cell (PBMC) Adenosine A3 Receptor (A3AR) Expression and Clinical Effects of CF102
timeFrame: Baseline to Day 28
Other outcomes:
Locations:
city: Tel Aviv
country: Israel
facility: Rabin Medical Center
Study officials:
affiliation: Can-Fite BioPharma Ltd
name: Michael H Silverman, MD
role: STUDY_DIRECTOR
affiliation: Rabin Medical Center
name: Salomon Shtemmer, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bar-Yehuda S, Stemmer SM, Madi L, Castel D, Ochaion A, Cohen S, Barer F, Zabutti A, Perez-Liz G, Del Valle L, Fishman P. The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. Int J Oncol. 2008 Aug;33(2):287-95.
citation: Stemmer SM, Benjaminov O, Medalia G, Ciuraru NB, Silverman MH, Bar-Yehuda S, Fishman S, Harpaz Z, Farbstein M, Cohen S, Patoka R, Singer B, Kerns WD, Fishman P. CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study. Oncologist. 2013;18(1):25-6. doi: 10.1634/theoncologist.2012-0211. Epub 2013 Jan 8.